Mitochondria as playmakers of apoptosis, autophagy and senescence
Mitochondria are the key energy-producing organelles and cellular source of reactive
species. They are responsible for managing cell life and death by a balanced homeostasis …
species. They are responsible for managing cell life and death by a balanced homeostasis …
Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists …
AR Sepulveda, SR Hamilton, CJ Allegra… - American journal of …, 2017 - academic.oup.com
Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …
review of the literature to establish standard molecular biomarker testing of colorectal cancer …
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
N McGranahan, C Swanton - Cancer cell, 2015 - cell.com
Precision medicine requires an understanding of cancer genes and mutational processes,
as well as an appreciation of the extent to which these are found heterogeneously in cancer …
as well as an appreciation of the extent to which these are found heterogeneously in cancer …
The causes and consequences of genetic heterogeneity in cancer evolution
Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …
Tumour heterogeneity in the clinic
Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …
genotype variations between patients, called interpatient heterogeneity, that predict the …
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Purpose: We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized,
cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and …
cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and …
[HTML][HTML] A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis
M Fujii, M Shimokawa, S Date, A Takano, M Matano… - Cell stem cell, 2016 - cell.com
Colorectal tumor is a heterogeneous disease, with varying clinical presentation and
prognosis in patients. To establish a platform encompassing this diversity, we generated 55 …
prognosis in patients. To establish a platform encompassing this diversity, we generated 55 …
Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma
Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies,
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …
An analysis of genetic heterogeneity in untreated cancers
Genetic intratumoural heterogeneity is a natural consequence of imperfect DNA replication.
Any two randomly selected cells, whether normal or cancerous, are therefore genetically …
Any two randomly selected cells, whether normal or cancerous, are therefore genetically …